Cookies show us what works. Privacy
Cookies show us what works. Privacy
29 funds hold it · Insiders net selling
Net selling: insiders sold $4.7M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net buying of $1K to $15K in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 4, 2026
Period ending
Sep 30, 2026
Earnings per share
-$2.11 expected
Revenue
Financial statements: Alpha Vantage
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 4, 2026 | -$1.99est. -$2.11 | +5.69%beat | $0.00Alpha Vantage | No year-ago quarter |
| Jun 30, 2026Reported Aug 5, 2026 | -$1.97est. -$2.10 | +6.06%beat | $0.00Alpha Vantage | No year-ago quarter |
| Mar 31, 2026Reported May 6, 2026 | -$2.30est. -$1.77 | -29.65%miss | $0.00Alpha Vantage | No year-ago quarter |
| Dec 31, 2025Reported Feb 24, 2026 | -$1.80est. -$1.50 | -19.73%miss | $0.00Alpha Vantage | No year-ago quarter |
| Sep 30, 2025Reported Nov 4, 2025 | -$1.56est. -$1.24 | -25.81%miss | $0.00Alpha Vantage | No year-ago quarter |
| Jun 30, 2025Reported Aug 6, 2025 | -$1.22est. -$1.16 | -5.17%miss | $0.00Alpha Vantage | No year-ago quarter |
| Mar 31, 2025Reported May 7, 2025 | -$1.04est. -$0.97 | -7.22%miss | $0.00Alpha Vantage | No year-ago quarter |
| Dec 31, 2024Reported Feb 25, 2025 | -$1.02est. -$0.99 | -2.58%miss | $0.00Alpha Vantage | -100.0%from $14.4M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $0 | $0 | $0 | $0 |
| Cost of what it sold | -$5.0M | $5.9M | — | — |
| Gross profit | $5.0M | -$5.9M | — | — |
| What it spent | ||||
| Research and development | $242.1M | $312.8M | $267.9M | $270.3M |
| Sales and admin | $32.2M | $33.1M | $34.9M | $37.9M |
| Other operating costs | $5.0M | -$5.9M | — | — |
| Total operating expenses | $279.3M | $340.0M | $302.8M | $308.3M |
| What was left | ||||
| Operating profit | -$274.3M | -$345.9M | -$302.8M | -$308.3M |
| Profit before tax | -$246.5M | -$320.6M | -$284.3M | -$297.1M |
| Net profit | -$246.5M | -$320.6M | -$284.3M | -$297.1M |
| EBITDA | -$236.7M | -$314.8M | -$289.5M | -$291.3M |
This stock is in a strong uptrend.
Trend
Strong uptrend
80 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
Vaxcyte’s VAX-31 Pneumococcal Vaccine Meets All Phase 3 Primary Goals
BullishNov 13Vaxcyte Stock After Wider Q3 Losses Has The Bull Case Changed?
Leans bearishNov 13Form 144 Vaxcyte For: 12 November By Investing.com
NeutralNov 13A 17,000-share sale is planned by Vaxcyte (PCVX) officer Harpreet S. Dhaliwal.
NeutralNov 12PCVX: VAX-31 data support a broad-coverage PCV, with adult BLA targeted for H1 2028
BullishNov 10Weekly Recap: VAX-31 meets OPUS-1 goals and R&D costs rise 54%
BullishNov 10Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: T. Rowe Price Investment Management, Inc.
NeutralNov 6T. Rowe Price updates its reported Vaxcyte (PCVX) stake; one fund holds 5.2%.
NeutralNov 612 macro signals shaping PCVX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results